Skip to main content
Contact Us
Subscribe
E-Edition
40°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by AlloVir, Inc.
AlloVir to Present at the Piper Sandler 35th Annual Healthcare Conference
November 16, 2023
From
AlloVir, Inc.
Via
Business Wire
Tickers
ALVR
AlloVir Reports Third Quarter 2023 Financial Results
November 02, 2023
From
AlloVir, Inc.
Via
Business Wire
Tickers
ALVR
AlloVir to Present at Upcoming Investor Conferences
August 28, 2023
From
AlloVir, Inc.
Via
Business Wire
Tickers
ALVR
AlloVir Reports Second Quarter 2023 Financial Results
August 03, 2023
From
AlloVir, Inc.
Via
Business Wire
Tickers
ALVR
AlloVir Announces Pricing of Public Offering of Common Stock
June 21, 2023
From
AlloVir, Inc.
Via
Business Wire
Tickers
ALVR
AlloVir Announces Proposed Public Offering of Common Stock
June 21, 2023
From
AlloVir, Inc.
Via
Business Wire
Tickers
ALVR
AlloVir Presents Positive Final Results From A Phase 2 Randomized, Placebo-Controlled Trial Evaluating Posoleucel Treatment of BK Infection in Kidney Transplant Recipients at the American Transplant Congress (ATC 2023)
June 05, 2023
From
AlloVir, Inc.
Via
Business Wire
Tickers
ALVR
AlloVir to Present at the BofA Securities 2023 Health Care Conference
May 01, 2023
From
AlloVir, Inc.
Via
Business Wire
Tickers
ALVR
AlloVir Announces Positive Results Including Long-Term Mortality Data in Phase 2 Posoleucel Multi-Virus Prevention Study in Oral Presentation at EBMT 2023
April 26, 2023
From
AlloVir, Inc.
Via
Business Wire
Tickers
ALVR
AlloVir Reports Full-Year 2022 Financial Results and 2023 Outlook
February 15, 2023
From
AlloVir, Inc.
Via
Business Wire
Tickers
ALVR
AlloVir Announces Positive Final Results from Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Posoleucel in Kidney Transplant Recipients with BK Viremia
February 15, 2023
From
AlloVir, Inc.
Via
Business Wire
Tickers
ALVR
AlloVir to Participate in the SVB Securities Global Biopharma Conference
February 01, 2023
From
AlloVir, Inc.
Via
Business Wire
Tickers
ALVR
AlloVir Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023
January 09, 2023
From
AlloVir, Inc.
Via
Business Wire
Tickers
ALVR
AlloVir to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
AlloVir, Inc.
Via
Business Wire
Tickers
ALVR
Final Data from AlloVir’s Phase 2 Study of Posoleucel for Multi-Virus Prevention to be Highlighted in Oral Presentation at 64th American Society of Hematology Annual Meeting
November 03, 2022
From
AlloVir, Inc.
Via
Business Wire
Tickers
ALVR
AlloVir Reports Third Quarter 2022 Financial Results
November 03, 2022
From
AlloVir, Inc.
Via
Business Wire
Tickers
ALVR
AlloVir to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
August 31, 2022
From
AlloVir, Inc.
Via
Business Wire
Tickers
ALVR
AlloVir Reports Second Quarter 2022 Financial Results
August 04, 2022
From
AlloVir, Inc.
Via
Business Wire
Tickers
ALVR
AlloVir Announces $126.6 Million Registered Direct Offering
July 27, 2022
From
AlloVir, Inc.
Via
Business Wire
Tickers
ALVR
AlloVir Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients
June 07, 2022
From
AlloVir, Inc.
Via
Business Wire
Tickers
ALVR
AlloVir Reports First Quarter 2022 Financial Results
May 05, 2022
From
AlloVir, Inc.
Via
Business Wire
Tickers
ALVR
AlloVir to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
November 15, 2021
From
AlloVir, Inc.
Via
Business Wire
Tickers
ALVR
FDA Grants Orphan Drug Designation (ODD) to AlloVir’s Posoleucel, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy, for the Treatment of Virus-Associated Hemorrhagic Cystitis
October 04, 2021
From
AlloVir, Inc.
Via
Business Wire
Tickers
ALVR
Data Presented at IDWeek™ 2021 Demonstrate that ALVR109, AlloVir’s Investigational SARS-CoV-2-Specific T Cell Therapy, Is Reactive Against a Broad Range of Variants, Including Delta
September 29, 2021
From
AlloVir, Inc.
Via
Business Wire
Tickers
ALVR
AlloVir to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
September 07, 2021
From
AlloVir, Inc.
Via
Business Wire
Tickers
ALVR
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.